Armetheon raises $7m to revive ARYx's Phase III anticoagulant
This article was originally published in Scrip
Executive Summary
A four-years-delayed Phase III clinical trial for the oral anticoagulant (OAC) tecarfarin is back on track now that Menlo Park, California-based Armetheon has raised a $7m Series A venture capital round to back what it sees as a better alternative to the standard of care, warfarin.